Insulin resistance and Alzheimer's disease: Bioenergetic linkages

Frontiers in Aging Neuroscience

Volumn 9, Issue OCT, 2017, Pages

  Neth, Bryan J ^a   Craft, Suzanne ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Bioenergetic shift; Inflammation; Insulin resistance; Ketone body; Metabolism; Positron emission tomography

Indexed keywords

INSULIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; BIOENERGY; BRAIN METABOLISM; CHRONIC INFLAMMATION; COGNITION; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERMETABOLISM; INSULIN RESISTANCE; NEUROIMAGING; NONHUMAN; PATHOGENESIS; REVIEW; VASCULAR DISEASE;

EID: 85032743717     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2017.00345     Document Type: Review

References (279)

1. Abbatecola, A. M., Paolisso, G., Lamponi, M., Bandinelli, S., Lauretani, F., Launer, L., et al. (2004). Insulin resistance and executive dysfunction in older persons. J. Am. Geriatr. Soc. 52, 1713-1718. doi: 10.1111/j.1532-5415.2004.52466.x.
2. Abbott, M. A., Wells, D. G., and Fallon, J. R. (1999). The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J. Neurosci. 19, 7300-7308.
3. 2, reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep. 41, 560-567. doi: 10.5483/bmbrep.2008.41.8.560
4. Agrawal, R., Tyagi, E., Shukla, R., and Nath, C. (2011). Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model. Eur. Neuropsychopharmacol. 21, 261-273. doi: 10.1016/j.euroneuro.2010.11.009.
5. Akash, M. S., Rehman, K., and Chen, S. (2013). Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J. Cell. Biochem. 114, 525-531. doi: 10.1002/jcb.24402.
6. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., et al. (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421. doi: 10.1016/S0197-4580(00)00124-X.
7. Alzheimer's Association. (2015). 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 11, 332-384. doi: 10.1016/j.jalz.2015.02.003.
8. Amador-Ortiz, C., Lin, W. L., Ahmed, Z., Personett, D., Davies, P., Duara, R., et al. (2007). TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 61, 435-445. doi: 10.1002/ana.21154.
9. Amor, S., Puentes, F., Baker, D., and Van Der Valk, P. (2010). Inflammation in neurodegenerative diseases. Immunology 129, 154-169. doi: 10.1111/j.1365-2567.2009.03225.x.
10. Apelt, J., Mehlhorn, G., and Schliebs, R. (1999). Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J. Neurosci. Res. 57, 693-705. doi: 10.1002/(sici)1097-4547(19990901)57:5<693::aid-jnr11>3.0.co;2-x.
11. Armstrong, R. A. (2011). The Pathogenesis of Alzheimer's disease: a reevaluation of the "amyloid cascade hypothesis". Int. J. Alzheimers Dis. 2011:630865. doi: 10.4061/2011/630865.
12. Ashraf, A., Fan, Z., Brooks, D. J., and Edison, P. (2015). Cortical hypermetabolism in MCI subjects: a compensatory mechanism? Eur. J. Nucl. Med. Mol. Imaging 42, 447-458. doi: 10.1007/s00259-014-2919-z.
13. Attwell, D., and Laughlin, S. B. (2001). An energy budget for signaling in the grey matter of the brain. J. Cereb. Blood Flow Metab. 21, 1133-1145. doi: 10.1097/00004647-200110000-00001.
14. Authier, F., Posner, B. I., and Bergeron, J. J. (1996). Insulin-degrading enzyme. Clin. Invest. Med. 19, 149-160.
15. Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., and Craft, S. (2011). Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68, 51-57. doi: 10.1001/archneurol.2010.225.
16. Banks, W. A., Jaspan, J. B., Huang, W., and Kastin, A. J. (1997a). Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18, 1423-1429. doi: 10.1016/s0196-9781(97)00231-3.
17. Banks, W. A., Jaspan, J. B., and Kastin, A. J. (1997b). Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 18, 1257-1262. doi: 10.1016/s0196-9781(97)00198-8.
18. Banks, W. A., Owen, J. B., and Erickson, M. A. (2012). Insulin in the brain: There and back again. Pharmacol. Ther. 136, 82-93. doi: 10.1016/j.pharmthera.2012.07.006.
19. Barros, L. F. (2013). Metabolic signaling by lactate in the brain. Trends Neurosci. 36, 396-404. doi: 10.1016/j.tins.2013.04.002.
20. Baskin, D. G., Figlewicz, D. P., Woods, S. C., Porte, D. Jr., and Dorsa, D. M. (1987). Insulin in the brain. Annu. Rev. Physiol. 49, 335-347. doi: 10.1146/annurev.ph.49.030187.002003.
21. Baura, G. D., Foster, D. M., Porte, D. Jr., Kahn, S. E., Bergman, R. N., Cobelli, C., et al. (1993). Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J. Clin. Invest. 92, 1824-1830. doi: 10.1172/jci116773.
22. Bélanger, M., Allaman, I., and Magistretti, P. J. (2011). Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 14, 724-738. doi: 10.1016/j.cmet.2011.08.016.
23. Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., et al. (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334. doi: 10.1016/j.psyneuen.2004.04.003.
24. Benedict, C., Kern, W., Schultes, B., Born, J., and Hallschmid, M. (2008). Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J. Clin. Endocrinol. Metab. 93, 1339-1344. doi: 10.1210/jc.2007-2606.
25. Bentourkia, M., Tremblay, S., Pifferi, F., Rousseau, J., Lecomte, R., and Cunnane, S. (2009). PET study of 11C-acetoacetate kinetics in rat brain during dietary treatments affecting ketosis. Am. J. Physiol. Endocrinol. Metab. 296, E796-E801. doi: 10.1152/ajpendo.90644.2008.
26. Berti, V., Murray, J., Davies, M., Spector, N., Tsui, W. H., Li, Y., et al. (2015). Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals. J. Nutr. Health Aging 19, 413-423. doi: 10.1007/s12603-014-0534-0.
27. Bezprozvanny, I., and Mattson, M. P. (2008). Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 31, 454-463. doi: 10.1016/j.tins.2008.06.005.
28. Biessels, G. J., Strachan, M. W., Visseren, F. L., Kappelle, L. J., and Whitmer, R. A. (2014). Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2, 246-255. doi: 10.1016/s2213-8587(13)70088-3.
29. Bingham, E. M., Hopkins, D., Smith, D., Pernet, A., Hallett, W., Reed, L., et al. (2002). The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 51, 3384-3390. doi: 10.2337/diabetes.51.12.3384.
30. Blasko, I., Stampfer-Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., and Grubeck-Loebenstein, B. (2004). How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 3, 169-176. doi: 10.1111/j.1474-9728.2004.00101.x.
31. Blass, J. P. (2000). The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann. N Y Acad. Sci. 924, 170-183. doi: 10.1111/j.1749-6632.2000.tb05576.x.
32. Blass, J. P., and Gibson, G. E. (1991). The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev. Neurol. (Paris) 147, 513-525.
33. Blázquez, E., Velázquez, E., Hurtado-Carneiro, V., and Ruiz-Albusac, J. M. (2014). Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front. Endocrinol. (Lausanne) 5:161. doi: 10.3389/fendo.2014.00161.
34. Blomqvist, G., Alvarsson, M., Grill, V., Von Heijne, G., Ingvar, M., Thorell, J. O., et al. (2002). Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients. Am. J. Physiol. Endocrinol. Metab. 283, E20-E28. doi: 10.1152/ajpendo.00294.2001.
35. Blomqvist, G., Thorell, J. O., Ingvar, M., Grill, V., Widen, L., and Stone-Elander, S. (1995). Use of R-ß-[1-11C]hydroxybutyrate in PET studies of regional cerebral uptake of ketone bodies in humans. Am. J. Physiol. 269, E948-E959.
36. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., and Riederer, P. (1995). Interleukin-1 ß and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202, 17-20. doi: 10.1016/0304-3940(95)12192-7.
37. Bohnen, N. I., Djang, D. S., Herholz, K., Anzai, Y., and Minoshima, S. (2012). Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J. Nucl. Med. 53, 59-71. doi: 10.2967/jnumed.111.096578.
38. Borghammer, P., Hansen, S. B., Eggers, C., Chakravarty, M., Vang, K., Aanerud, J., et al. (2012). Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurol. Scand. 125, 303-310. doi: 10.1111/j.1600-0404.2011.01556.x.
39. Bosco, D., Fava, A., Plastino, M., Montalcini, T., and Pujia, A. (2011). Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 15, 1807-1821. doi: 10.1111/j.1582-4934.2011.01318.x.
40. Boumezbeur, F., Petersen, K. F., Cline, G. W., Mason, G. F., Behar, K. L., Shulman, G. I., et al. (2010). The contribution of blood lactate to brain energy metabolism in humans measured by dynamic 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 30, 13983-13991. doi: 10.1523/JNEUROSCI.2040-10.2010.
41. Bowie, C. R., and Harvey, P. D. (2006). Administration and interpretation of the Trail Making Test. Nat. Protoc. 1, 2277-2281. doi: 10.1038/nprot.2006.390.
42. Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., and Del Tredici, K. (2006). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389-404. doi: 10.1007/s00401-006-0127-z.
43. Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259. doi: 10.1007/bf00308809.
44. Brant, A. M., Jess, T. J., Milligan, G., Brown, C. M., and Gould, G. W. (1993). Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system. Biochem. Biophys. Res. Commun. 192, 1297-1302. doi: 10.1006/bbrc.1993.1557.
45. Brinton, R. D. (2008a). Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv. Drug Deliv. Rev. 60, 1504-1511. doi: 10.1016/j.addr.2008.06.003.
46. Brinton, R. D. (2008b). The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 31, 529-537. doi: 10.1016/j.tins.2008.07.003.
47. Brown, A. M., and Ransom, B. R. (2007). Astrocyte glycogen and brain energy metabolism. Glia 55, 1263-1271. doi: 10.1002/glia.20557.
48. Burns, J. M., Church, J. A., Johnson, D. K., Xiong, C., Marcus, D., Fotenos, A. F., et al. (2005). White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch. Neurol. 62, 1870-1876. doi: 10.1001/archneur.62.12.1870.
49. Cahill, G. F. Jr. (2006). Fuel metabolism in starvation. Annu. Rev. Nutr. 26, 1-22. doi: 10.1146/annurev.nutr.26.061505.111258.
50. Cai, W., Sakaguchi, M., Kleinridders, A., Gonzalez-Del Pino, G., Dreyfuss, J. M., O'neill, B. T., et al. (2017). Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat. Commun. 8:14892. doi: 10.1038/ncomms14892.
51. Cardoso, S. M., Proenca, M. T., Santos, S., Santana, I., and Oliveira, C. R. (2004). Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging 25, 105-110. doi: 10.1016/s0197-4580(03)00033-2.
52. Castellano, C. A., Nugent, S., Paquet, N., Tremblay, S., Bocti, C., Lacombe, G., et al. (2015). Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. J. Alzheimers Dis. 43, 1343-1353. doi: 10.3233/JAD-141074.
53. Chaturvedi, R. K., and Beal, M. F. (2013). Mitochondrial diseases of the brain. Free Radic. Biol. Medi.ine 63, 1-29. doi: 10.1016/j.freeradbiomed.2013.03.018.
54. Cheng, G., Huang, C., Deng, H., and Wang, H. (2012). Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern. Med. J. 42, 484-491. doi: 10.1111/j.1445-5994.2012.02758.x.
55. Chen, Z., and Zhong, C. (2013). Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 108, 21-43. doi: 10.1016/j.pneurobio.2013.06.004.
56. Cholerton, B., Baker, L. D., and Craft, S. (2011). Insulin resistance and pathological brain ageing. Diabet. Med. 28, 1463-1475. doi: 10.1111/j.1464-5491.2011.03464.x.
57. Cholerton, B., Baker, L. D., and Craft, S. (2013). Insulin, cognition, and dementia. Eur. J. Pharmacol. 719, 170-179. doi: 10.1016/j.ejphar.2013.08.008.
58. Cistaro, A., Valentini, M. C., Chiò, A., Nobili, F., Calvo, A., Moglia, C., et al. (2012). Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur. J. Nucl. Med. Mol. Imaging 39, 251-259. doi: 10.1007/s00259-011-1979-6.
59. Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., et al. (2015). Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J. Alzheimers Dis. 44, 897-906. doi: 10.3233/JAD-141791.
60. Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., et al. (2013). Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J. Alzheimers Dis. 35, 789-797. doi: 10.3233/JAD-122308.
61. Convit, A., Wolf, O. T., Tarshish, C., and de Leon, M. J. (2003). Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc. Natl. Acad. Sci. U S A 100, 2019-2022. doi: 10.1073/pnas.0336073100.
62. Cook, D. G., Leverenz, J. B., McMillan, P. J., Kulstad, J. J., Ericksen, S., Roth, R. A., et al. (2003). Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-e4 allele. Am. J. Pathol. 162, 313-319. doi: 10.1016/s0002-9440(10)63822-9.
63. Cooper, G. J., Day, A. J., Willis, A. C., Roberts, A. N., Reid, K. B., and Leighton, B. (1989). Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. Biochim. Biophys. Acta 1014, 247-258. doi: 10.1016/0167-4889(89)90220-6.
64. Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., et al. (2012). Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res. 1441, 64-78. doi: 10.1016/j.brainres.2011.12.063.
65. Craft, S. (2007). Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4, 147-152. doi: 10.2174/156720507780362137.
66. Craft, S. (2009). The role of metabolic disorders in Alzheimer disease and vascular dementia. Arch. Neurol. 66, 300-305. doi: 10.1001/archneurol.2009.27.
67. Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M., Purganan, K., et al. (2003). Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28, 809-822. doi: 10.1016/s0306-4530(02)00087-2.
68. Craft, S., Asthana, S., Newcomer, J. W., Wilkinson, C. W., Matos, I. T., Baker, L. D., et al. (1999). Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 56, 1135-1140. doi: 10.1001/archpsyc.56.12.1135.
69. Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G. S., Claxton, A., et al. (2012). Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29-38. doi: 10.1001/archneurol.2011.233.
70. Craft, S., Cholerton, B., and Baker, L. D. (2013). Insulin and Alzheimer's disease: untangling the web. J. Alzheimers Dis. 33, S263-S275. doi: 10.3233/JAD-2012-129042.
71. Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., et al. (1996). Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol. Aging 17, 123-130. doi: 10.1016/0197-4580(95)02002-0.
72. Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., and Porte, D. Jr. (1998). Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168. doi: 10.1212/wnl.50.1.164.
73. Craft, S., and Watson, G. S. (2004). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3, 169-178. doi: 10.1016/s1474-4422(04)00681-7.
74. Cui, H., Kong, Y., and Zhang, H. (2012). Oxidative stress, mitochondrial dysfunction, and aging. J. Signal Transduct. 2012:646354. doi: 10.1155/2012/646354.
75. Cunnane, S. C., Courchesne-Loyer, A., St-Pierre, V., Vandenberghe, C., Pierotti, T., Fortier, M., et al. (2016). Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease. Ann. N Y Acad. Sci. 1367, 12-20. doi: 10.1111/nyas.12999.
76. Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., et al. (2011). Brain fuel metabolism, aging and Alzheimer's disease. Nutrition 27, 3-20. doi: 10.1016/j.nut.2010.07.021.
77. De Felice, F. G., and Ferreira, S. T. (2014). Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63, 2262-2272. doi: 10.2337/db13-1954.
78. De Felice, F. G., and Lourenco, M. V. (2015). Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease. Front. Aging Neurosci. 7:94. doi: 10.3389/fnagi.2015.00094.
79. De Felice, F. G., Vieira, M. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., et al. (2009). Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aß oligomers. Proc. Natl. Acad. Sci. U S A 106, 1971-1976. doi: 10.1073/pnas.0809158106.
80. DeFronzo, R. A. (2010). Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53, 1270-1287. doi: 10.1007/s00125-010-1684-1.
81. DeFronzo, R. A., Bonadonna, R. C., and Ferrannini, E. (1992). Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318-368. doi: 10.2337/diacare.15.3.318.
82. DeFronzo, R. A., and Ferrannini, E. (1991). Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173-194. doi: 10.2337/diacare.14.3.173.
83. Despa, S., Margulies, K. B., Chen, L., Knowlton, A. A., Havel, P. J., Taegtmeyer, H., et al. (2012). Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ. Res. 110, 598-608. doi: 10.1161/CIRCRESAHA.111.258285.
84. Devi, L., Alldred, M. J., Ginsberg, S. D., and Ohno, M. (2012). Mechanisms underlying insulin deficiency-induced acceleration of ß-amyloidosis in a mouse model of Alzheimer's disease. PLoS One 7:e32792. doi: 10.1371/journal.pone.0032792.
85. Devraj, K., Klinger, M. E., Myers, R. L., Mokashi, A., Hawkins, R. A., and Simpson, I. A. (2011). GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J. Neurosci. Res. 89, 1913-1925. doi: 10.1002/jnr.22738.
86. Di Paolo, G., and Kim, T. W. (2011). Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 12, 284-296. doi: 10.1038/nrn3012.
87. Ding, F., Yao, J., Rettberg, J. R., Chen, S., and Brinton, R. D. (2013a). Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. PLoS One 8:e79977. doi: 10.1371/journal.pone.0079977.
88. Ding, F., Yao, J., Zhao, L., Mao, Z., Chen, S., and Brinton, R. D. (2013b). Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. PLoS One 8:e59825. doi: 10.1371/journal.pone.0059825.
89. Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311-321. doi: 10.1056/NEJMoa1312889.
90. Dou, J. T., Chen, M., Dufour, F., Alkon, D. L., and Zhao, W. Q. (2005). Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn. Mem. 12, 646-655. doi: 10.1101/lm.88005.
91. Duarte, A. I., Moreira, P. I., and Oliveira, C. R. (2012). Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res. 2012:384017. doi: 10.1155/2012/384017.
92. Edland, S. D., Silverman, J. M., Peskind, E. R., Tsuang, D., Wijsman, E., and Morris, J. C. (1996). Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology 47, 254-256. doi: 10.1212/WNL.47.1.254.
93. El Messari, S., Leloup, C., Quignon, M., Brisorgueil, M. J., Penicaud, L., and Arluison, M. (1998). Immunocytochemical localization of the insulin-responsive glucose transporter 4 (Glut4) in the rat central nervous system. J. Comp. Neurol. 399, 492-512. doi: 10.1002/(sici)1096-9861(19981005)399:4<492::aid-cne4>3.0.co;2-x.
94. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., et al. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid ß-protein, and the ß-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U S A 100, 4162-4167. doi: 10.1073/pnas.0230450100.
95. Festa, A., D'agostino, R. Jr., Howard, G., Mykkänen, L., Tracy, R. P., and Haffner, S. M. (2000). Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42-47. doi: 10.1161/01.cir.102.1.42.
96. Figlewicz, D. P., Szot, P., Israel, P. A., Payne, C., and Dorsa, D. M. (1993). Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 602, 161-164. doi: 10.1016/0006-8993(93)90258-o.
97. Fratiglioni, L., Ahlbom, A., Viitanen, M., and Winblad, B. (1993). Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Ann Neurol 33, 258-266. doi: 10.1002/ana.410330306.
98. Freiherr, J., Hallschmid, M., Frey, W. H. II, Brunner, Y. F., Chapman, C. D., Holscher, C., et al. (2013). Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27, 505-514. doi: 10.1007/s40263-013-0076-8.
99. Fukao, T., Song, X. Q., Mitchell, G. A., Yamaguchi, S., Sukegawa, K., Orii, T., et al. (1997). Enzymes of ketone body utilization in human tissues: protein and messenger RNA levels of succinyl-coenzyme A (CoA):3-ketoacid CoA transferase and mitochondrial and cytosolic acetoacetyl-CoA thiolases. Pediatr. Res. 42, 498-502. doi: 10.1203/00006450-199710000-00013.
100. Garber, A. J., Menzel, P. H., Boden, G., and Owen, O. E. (1974). Hepatic ketogenesis and gluconeogenesis in humans. J. Clin. Invest. 54, 981-989. doi: 10.1172/jci107839.
101. Garwood, C. J., Ratcliffe, L. E., Morgan, S. V., Simpson, J. E., Owens, H., Vazquez-Villaseñor, I., et al. (2015). Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors. Mol. Brain 8:51. doi: 10.1186/s13041-015-0138-6.
102. Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., et al. (2001). Stimulation of ß-amyloid precursor protein trafficking by insulin reduces intraneuronal ß-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21, 2561-2570.
103. Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., et al. (2011). APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry 16, 903-907. doi: 10.1038/mp.2011.52.
104. Ghasemi, R., Dargahi, L., Haeri, A., Moosavi, M., Mohamed, Z., and Ahmadiani, A. (2013a). Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol. Neurobiol. 47, 1045-1065. doi: 10.1007/s12035-013-8404-z.
105. Ghasemi, R., Haeri, A., Dargahi, L., Mohamed, Z., and Ahmadiani, A. (2013b). Insulin in the brain: sources, localization and functions. Mol. Neurobiol. 47, 145-171. doi: 10.1007/s12035-012-8339-9.
106. Gillette-Guyonnet, S., Nourhashemi, F., Andrieu, S., de Glisezinski, I., Ousset, P. J., Riviere, D., et al. (2000). Weight loss in Alzheimer disease. Am. J. Clin. Nutr. 71, 637s-642s.
107. Gilman, S., Junck, L., Markel, D. S., Koeppe, R. A., and Kluin, K. J. (1990). Cerebral glucose hypermetabolism in Friedreich's ataxia detected with positron emission tomography. Ann. Neurol. 28, 750-757. doi: 10.1002/ana.410280605.
108. Goldin, A., Beckman, J. A., Schmidt, A. M., and Creager, M. A. (2006). Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114, 597-605. doi: 10.1161/circulationaha.106.621854.
109. Gonzalez, S. V., Nguyen, N. H., Rise, F., and Hassel, B. (2005). Brain metabolism of exogenous pyruvate. J. Neurochem. 95, 284-293. doi: 10.1111/j.1471-4159.2005.03365.x.
110. Greenwood, C. E., and Winocur, G. (2001). Glucose treatment reduces memory deficits in young adult rats fed high-fat diets. Neurobiol. Learn. Mem. 75, 179-189. doi: 10.1006/nlme.2000.3964.
111. Haier, R. J., Alkire, M. T., White, N. S., Uncapher, M. R., Head, E., Lott, I. T., et al. (2003). Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology 61, 1673-1679. doi: 10.1212/01.wnl.0000098935.36984.25.
112. Haier, R. J., Head, K., Head, E., and Lott, I. T. (2008). Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage 39, 1324-1332. doi: 10.1016/j.neuroimage.2007.09.064.
113. Haj-ali, V., Mohaddes, G., and Babri, S. H. (2009). Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats. Behav. Neurosci. 123, 1309-1314. doi: 10.1037/a0017722.
114. Halestrap, A. P., and Wilson, M. C. (2012). The monocarboxylate transporter family-role and regulation. IUBMB Life 64, 109-119. doi: 10.1002/iub.572.
115. Hardy, J. A., and Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185. doi: 10.1126/science.1566067.
116. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994.
117. Hassing, L. B., Grant, M. D., Hofer, S. M., Pedersen, N. L., Nilsson, S. E., Berg, S., et al. (2004). Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J. Int. Neuropsychol. Soc. 10, 599-607. doi: 10.1017/S1355617704104165.
118. Havrankova, J., Roth, J., and Brownstein, M. (1978a). Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272, 827-829. doi: 10.1038/272827a0.
119. Havrankova, J., Schmechel, D., Roth, J., and Brownstein, M. (1978b). Identification of insulin in rat brain. Proc. Natl. Acad. Sci. U S A 75, 5737-5741. doi: 10.1073/pnas.75.11.5737.
120. Hirvonen, J., Virtanen, K. A., Nummenmaa, L., Hannukainen, J. C., Honka, M. J., Bucci, M., et al. (2011). Effects of insulin on brain glucose metabolism in impaired glucose tolerance. Diabetes 60, 443-447. doi: 10.2337/db10-0940.
121. Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., et al. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18, 902-904. doi: 10.1096/fj.03-0978fje.
122. Houten, S. M., and Wanders, R. J. (2010). A general introduction to the biochemistry of mitochondrial fatty acid ß-oxidation. J. Inherit. Metab. Dis. 33, 469-477. doi: 10.1007/s10545-010-9061-2.
123. Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., et al. (2012). Donepezil and memantine for moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 366, 893-903. doi: 10.1056/NEJMoa1106668.
124. Ito, S., Ohtsuki, S., and Terasaki, T. (2006). Functional characterization of the brain-to-blood efflux clearance of human amyloid-ß peptide (1-40) across the rat blood-brain barrier. Neurosci. Res. 56, 246-252. doi: 10.1016/j.neures.2006.07.006.
125. Jackson, K., Barisone, G. A., Diaz, E., Jin, L. W., DeCarli, C., and Despa, F. (2013). Amylin deposition in the brain: a second amyloid in Alzheimer disease? Ann. Neurol. 74, 517-526. doi: 10.1002/ana.23956.
126. Johnson, D. K., Wilkins, C. H., and Morris, J. C. (2006). Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch. Neurol. 63, 1312-1317. doi: 10.1001/archneur.63.9.1312.
127. Johri, A., and Beal, M. F. (2012). Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 342, 619-630. doi: 10.1124/jpet.112.192138.
128. Kadish, I., Thibault, O., Blalock, E. M., Chen, K. C., Gant, J. C., Porter, N. M., et al. (2009). Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment. J. Neurosci. 29, 1805-1816. doi: 10.1523/JNEUROSCI.4599-08.2009.
129. Kamagate, A., Qu, S., Perdomo, G., Su, D., Kim, D. H., Slusher, S., et al. (2008). FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J. Clin. Invest. 118, 2347-2364. doi: 10.1172/JCI32914.
130. Karch, C. M., Jeng, A. T., Nowotny, P., Cady, J., Cruchaga, C., and Goate, A. M. (2012). Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One 7:e50976. doi: 10.1371/journal.pone.0050976.
131. Katakam, P. V. G., Snipes, J. A., Steed, M. M., and Busija, D. W. (2012). Insulin-induced generation of reactive oxygen species and uncoupling of nitric oxide synthase underlie the cerebrovascular insulin resistance in obese rats. J. Cereb. Blood Flow Metab. 32, 792-804. doi: 10.1038/jcbfm.2011.181.
132. Kern, W., Peters, A., Fruehwald-Schultes, B., Deininger, E., Born, J., and Fehm, H. L. (2001). Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 74, 270-280. doi: 10.1159/000054694.
133. Kerti, L., Witte, A. V., Winkler, A., Grittner, U., Rujescu, D., and Floel, A. (2013). Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 81, 1746-1752. doi: 10.1212/01.WNL.0000435561.00234.ee.
134. Ketterer, C., Tschritter, O., Preissl, H., Heni, M., Häring, H.-U., and Fritsche, A. (2011). Insulin sensitivity of the human brain. Diabetes Res. Clin. Pract. 93, S47-S51. doi: 10.1016/S0168-8227(11)70013-4.
135. Khansari, N., Shakiba, Y., and Mahmoudi, M. (2009). Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. 3, 73-80. doi: 10.2174/187221309787158371.
136. Kim, J. A., Wei, Y., and Sowers, J. R. (2008). Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 102, 401-414. doi: 10.1161/CIRCRESAHA.107.165472.
137. Kleinridders, A. (2016). Deciphering brain insulin receptor and insulin-like growth factor 1 receptor signalling. J. Neuroendocrinol. 28:11. doi: 10.1111/jne.12433.
138. Kleinridders, A., Ferris, H. A., Cai, W., and Kahn, C. R. (2014). Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63, 2232-2243. doi: 10.2337/db14-0568.
139. Kopf, S. R., and Baratti, C. M. (1999). Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol. Learn. Mem. 71, 50-61. doi: 10.1006/nlme.1998.3831.
140. Kubaszek, A., Pihlajamaki, J., Komarovski, V., Lindi, V., Lindström, J., Eriksson, J., et al. (2003). Promoter polymorphisms of the TNF-a (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52, 1872-1876. doi: 10.2337/diabetes.52.7.1872.
141. Kurochkin, I. V., and Goto, S. (1994). Alzheimer's ß-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345, 33-37. doi: 10.1016/0014-5793(94)00387-4.
142. Lee, J. (2013). Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes. Arch. Pharm. Res. 36, 208-222. doi: 10.1007/s12272-013-0023-8.
143. Lee, C. C., Kuo, Y. M., Huang, C. C., and Hsu, K. S. (2009). Insulin rescues amyloid ß-induced impairment of hippocampal long-term potentiation. Neurobiol. Aging 30, 377-387. doi: 10.1016/j.neurobiolaging.2007.06.014.
144. Lee, S. J., Lee, W. Y., Kim, Y. K., An, Y. S., Cho, J. W., Choi, J. Y., et al. (2012). Apparent relative hypermetabolism of selective brain areas in Huntington disease and importance of reference region for analysis. Clin. Nucl. Med. 37, 663-668. doi: 10.1097/rlu.0b013e3182478bf2.
145. Lesnefsky, E. J., Moghaddas, S., Tandler, B., Kerner, J., and Hoppel, C. L. (2001). Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J. Mol. Cell. Cardiol. 33, 1065-1089. doi: 10.1006/jmcc.2001.1378.
146. Lim, Y. A., Rhein, V., Baysang, G., Meier, F., Poljak, A., Raftery, M. J., et al. (2010). Aß and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 10, 1621-1633. doi: 10.1002/pmic.200900651.
147. Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C.-X. (2011). Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 225, 54-62. doi: 10.1002/path.2912.
148. Livingstone, C., Lyall, H., and Gould, G. W. (1995). Hypothalamic GLUT 4 expression: a glucose- and insulin-sensing mechanism? Mol. Cell. Endocrinol. 107, 67-70. doi: 10.1016/0303-7207(94)03423-q.
149. Lowell, B. B., and Shulman, G. I. (2005). Mitochondrial dysfunction and type 2 diabetes. Science 307, 384-387. doi: 10.1126/science.1104343.
150. Lund-Andersen, H. (1979). Transport of glucose from blood to brain. Physiol. Rev. 59, 305-352.
151. Luo, F., Rustay, N. R., Ebert, U., Hradil, V. P., Cole, T. B., Llano, D. A., et al. (2012). Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol. Aging 33, 933-944. doi: 10.1016/j.neurobiolaging.2010.08.005.
152. Lüth, H. J., Ogunlade, V., Kuhla, B., Kientsch-Engel, R., Stahl, P., Webster, J., et al. (2005). Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb. Cortex 15, 211-220. doi: 10.1093/cercor/bhh123.
153. Madamanchi, N. R., and Runge, M. S. (2007). Mitochondrial dysfunction in atherosclerosis. Circ. Res. 100, 460-473. doi: 10.1161/01.RES.0000258450.44413.96.
154. Maimaiti, S., Frazier, H. N., Anderson, K. L., Ghoweri, A. O., Brewer, L. D., Porter, N. M., et al. (2017). Novel calcium-related targets of insulin in hippocampal neurons. Neuroscience 364, 130-142. doi: 10.1016/j.neuroscience.2017.09.019.
155. Mammucari, C., and Rizzuto, R. (2010). Signaling pathways in mitochondrial dysfunction and aging. Mech. Ageing Dev. 131, 536-543. doi: 10.1016/j.mad.2010.07.003.
156. McDermott, J. R., and Gibson, A. M. (1997). Degradation of Alzheimer's ß-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem. Res. 22, 49-56. doi: 10.1023/A:1027325304203.
157. Medina, D., DeToledo-Morrell, L., Urresta, F., Gabrieli, J. D., Moseley, M., Fleischman, D., et al. (2006). White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol. Aging 27, 663-672. doi: 10.1016/j.neurobiolaging.2005.03.026.
158. Montgomery, M. K., and Turner, N. (2015). Mitochondrial dysfunction and insulin resistance: an update. Endocr. Connect. 4, R1-R15. doi: 10.1530/ec-14-0092.
159. Morris, A. (2005). Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 28, 109-121. doi: 10.1007/s10545-005-5518-0.
160. Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486-510. doi: 10.1007/s00259-005-1762-7.
161. Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., et al. (2007). Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U S A 104, 19067-19072. doi: 10.1073/pnas.0705036104.
162. Mosconi, L., Mistur, R., Switalski, R., Brys, M., Glodzik, L., Rich, K., et al. (2009a). Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 72, 513-520. doi: 10.1212/01.wnl.0000333247.51383.43.
163. Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., et al. (2009b). FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811-822. doi: 10.1007/s00259-008-1039-z.
164. Mosconi, L., Pupi, A., and De Leon, M. J. (2008). Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. N Y Acad. Sci. 1147, 180-195. doi: 10.1196/annals.1427.007.
165. Muniyappa, R., Montagnani, M., Koh, K. K., and Quon, M. J. (2007). Cardiovascular actions of insulin. Endocr. Rev. 28, 463-491. doi: 10.1210/er.2007-0006.
166. Nagasaka, T., Nagasaka, K., Ohta, E., Shindo, K., Takiyama, Y., Shiozawa, Z., et al. (2011). Cerebral hypermetabolism demonstrated by FDG PET in familial Creutzfeldt-Jakob disease. Clin. Nucl. Med. 36, 725-727. doi: 10.1097/rlu.0b013e31821a2604.
167. Neumann, K. F., Rojo, L., Navarrete, L. P., Farías, G., Reyes, P., and Maccioni, R. B. (2008). Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 5, 438-447. doi: 10.2174/156720508785908919.
168. Novak, V., Milberg, W., Hao, Y., Munshi, M., Novak, P., Galica, A., et al. (2014). Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care 37, 751-759. doi: 10.2337/dc13-1672.
169. Nugent, S., Tremblay, S., Chen, K. W., Ayutyanont, N., Roontiva, A., Castellano, C. A., et al. (2014). Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiol. Aging 35, 1386-1395. doi: 10.1016/j.neurobiolaging.2013.11.027.
170. Oskarsson, M. E., Paulsson, J. F., Schultz, S. W., Ingelsson, M., Westermark, P., and Westermark, G. T. (2015). In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am. J. Pathol. 185, 834-846. doi: 10.1016/j.ajpath.2014.11.016.
171. Pan, J. W., Rothman, T. L., Behar, K. L., Stein, D. T., and Hetherington, H. P. (2000). Human brain ß-hydroxybutyrate and lactate increase in fasting-induced ketosis. J. Cereb. Blood Flow Metab. 20, 1502-1507. doi: 10.1097/00004647-200010000-00012.
172. Pancani, T., Anderson, K. L., Porter, N. M., and Thibault, O. (2011). Imaging of a glucose analog, calcium and NADH in neurons and astrocytes: dynamic responses to depolarization and sensitivity to pioglitazone. Cell Calcium 50, 548-558. doi: 10.1016/j.ceca.2011.09.002.
173. Park, C. R., Seeley, R. J., Craft, S., and Woods, S. C. (2000). Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 68, 509-514. doi: 10.1016/s0031-9384(99)00220-6.
174. Park, L. C., Zhang, H., Sheu, K. F., Calingasan, N. Y., Kristal, B. S., Lindsay, J. G., et al. (1999). Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia. J. Neurochem. 72, 1948-1958. doi: 10.1046/j.1471-4159.1999.0721948.x.
175. Parker, W. D. Jr., Filley, C. M., and Parks, J. K. (1990). Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40, 1302-1303. doi: 10.1212/WNL.40.8.1302.
176. Pellerin, L., Bouzier-Sore, A. K., Aubert, A., Serres, S., Merle, M., Costalat, R., et al. (2007). Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 55, 1251-1262. doi: 10.1002/glia.20528.
177. Pérez, A., Morelli, L., Cresto, J. C., and Castaño, E. M. (2000). Degradation of soluble amyloid ß-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 25, 247-255. doi: 10.1023/A:1007527721160.
178. Piroli, G. G., Grillo, C. A., Reznikov, L. R., Adams, S., McEwen, B. S., Charron, M. J., et al. (2007). Corticosterone impairs insulin-stimulated translocation of GLUT4 in the rat hippocampus. Neuroendocrinology 85, 71-80. doi: 10.1159/000101694.
179. Poisnel, G., Hérard, A. S., El Tannir El Tayara, N., Bourrin, E., Volk, A., Kober, F., et al. (2012). Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol. Aging 33, 1995-2005. doi: 10.1016/j.neurobiolaging.2011.09.026.
180. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E., and Ridker, P. M. (2001). C-reactive protein, interleukin 6 and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334. doi: 10.1001/jama.286.3.327.
181. Purdon, A. D., Rosenberger, T. A., Shetty, H. U., and Rapoport, S. I. (2002). Energy consumption by phospholipid metabolism in mammalian brain. Neurochem. Res. 27, 1641-1647. doi: 10.1023/A:1021635027211.
182. Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., et al. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid ß-protein by degradation. J. Biol. Chem. 273, 32730-32738. doi: 10.1074/jbc.273.49.32730.
183. Quarles, R. H., Macklin, W. B., and Morell, P. (2006). Myelin Formation, Structure and Biochemistry. London: Elsevier.
184. Ramasamy, R., Vannucci, S. J., Yan, S. S., Herold, K., Yan, S. F., and Schmidt, A. M. (2005). Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15, 16R-28R. doi: 10.1093/glycob/cwi053.
185. Reagan, L. P., Gorovits, N., Hoskin, E. K., Alves, S. E., Katz, E. B., Grillo, C. A., et al. (2001). Localization and regulation of GLUTx1 glucose transporter in the hippocampus of streptozotocin diabetic rats. Proc. Natl. Acad. Sci. U S A 98, 2820-2825. doi: 10.1073/pnas.051629798.
186. Reaven, G. M. (1983). Insulin resistance in noninsulin-dependent diabetes mellitus. Does it exist and can it be measured? Am. J. Med. 74, 3-17. doi: 10.1016/0002-9343(83)90650-2.
187. Reaven, G. M. (2003). The insulin resistance syndrome. Curr. Atheroscler. Rep. 5, 364-371. doi: 10.1007/s11883-003-0007-0.
188. Reddy, P. H. (2009). Amyloid ß, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp. Neurol. 218, 286-292. doi: 10.1016/j.expneurol.2009.03.042.
189. Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., and Jagust, W. (2014). Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 71, 195-200. doi: 10.1001/jamaneurol.2013.5390.
190. Reger, M. A., Watson, G. S., Frey, W. H., Baker, L. D., Cholerton, B., Keeling, M. L., et al. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiology of Aging 27, 451-458. doi: 10.1016/j.neurobiolaging.2005.03.016.
191. Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., et al. (2008). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-ß in memory-impaired older adults. J. Alzheimers Dis. 13, 323-331. doi: 10.3233/jad-2008-13309.
192. Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., et al. (1996). Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334, 752-758. doi: 10.1056/nejm199603213341202.
193. Reitz, C. (2013). Dyslipidemia and the risk of Alzheimer's disease. Curr. Atheroscler. Rep. 15:307. doi: 10.1007/s11883-012-0307-3.
194. Robinson, P. J., Noronha, J., DeGeorge, J. J., Freed, L. M., Nariai, T., and Rapoport, S. I. (1992). A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res. Brain Res. Rev. 17, 187-214. doi: 10.1016/0165-0173(92)90016-f.
195. Roden, M., Perseghin, G., Petersen, K. F., Hwang, J. H., Cline, G. W., Gerow, K., et al. (1996). The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J. Clin. Invest. 97, 642-648. doi: 10.1172/jci118460.
196. Rojas, S., Herance, J. R., Gispert, J. D., Abad, S., Torrent, E., Jiménez, X., et al. (2013). In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol. Aging 34, 1790-1798. doi: 10.1016/j.neurobiolaging.2012.12.027.
197. Roriz-Filho, J. S., Sá-Roriz, T. M., Rosset, I., Camozzato, A. L., Santos, A. C., Chaves, M. L. F., et al. (2009). (Pre)diabetes, brain aging and cognition. Biochim. Biophys. Acta 1792, 432-443. doi: 10.1016/j.bbadis.2008.12.003.
198. Roy, M., Nugent, S., Tremblay-Mercier, J., Tremblay, S., Courchesne-Loyer, A., Beaudoin, J.-F., et al. (2012). The ketogenic diet increases brain glucose and ketone uptake in aged rats A dual tracer PET and volumetric MRI study. Brain Res. 1488, 14-23. doi: 10.1016/j.brainres.2012.10.008.
199. Ryu, J. K., and McLarnon, J. G. (2009). A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J. Cell. Mol. Med. 13, 2911-2925. doi: 10.1111/j.1582-4934.2008.00434.x.
200. Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., et al. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333. doi: 10.1056/NEJMoa1304839.
201. Saltiel, A. R., and Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806. doi: 10.1038/414799a.
202. Sanchez-Mejia, R. O., Newman, J. W., Toh, S., Yu, G. Q., Zhou, Y., Halabisky, B., et al. (2008). Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 11, 1311-1318. doi: 10.1038/nn.2213.
203. Sasaki, N., Fukatsu, R., Tsuzuki, K., Hayashi, Y., Yoshida, T., Fujii, N., et al. (1998). Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 153, 1149-1155. doi: 10.1016/S0002-9440(10)65659-3.
204. Savage, D. B., Petersen, K. F., and Shulman, G. I. (2007). Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87, 507-520. doi: 10.1152/physrev.00024.2006.
205. Scheff, S. W., Price, D. A., Schmitt, F. A., and Mufson, E. J. (2006). Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 27, 1372-1384. doi: 10.1016/j.neurobiolaging.2005.09.012.
206. Schiöth, H. B., Craft, S., Brooks, S. J., Frey, W. H. II, and Benedict, C. (2012). Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol. Neurobiol. 46, 4-10. doi: 10.1007/s12035-011-8229-6.
207. Schneider, L. S., Dagerman, K. S., Higgins, J. P., and McShane, R. (2011a). Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch. Neurol. 68, 991-998. doi: 10.1001/archneurol.2011.69.
208. Schneider, L. S., Insel, P. S., and Weiner, M. W. (2011b). Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative. Arch. Neurol. 68, 58-66. doi: 10.1001/archneurol.2010.343.
209. Schönfeld, P., and Reiser, G. (2013). Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. J. Cereb. Blood Flow Metab. 33, 1493-1499. doi: 10.1038/jcbfm.2013.128.
210. Schulingkamp, R. J., Pagano, T. C., Hung, D., and Raffa, R. B. (2000). Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci. Biobehav. Rev. 24, 855-872. doi: 10.1016/s0149-7634(00)00040-3.
211. Schwartz, M., and Baruch, K. (2014). The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 33, 7-22. doi: 10.1002/embj.201386609.
212. Schwartz, M. W., Figlewicz, D. F., Kahn, S. E., Baskin, D. G., Greenwood, M. R., and Porte, D. Jr. (1990). Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 11, 467-472. doi: 10.1016/0196-9781(90)90044-6.
213. Selkoe, D. J. (1996). Amyloid ß-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271, 18295-18298. doi: 10.1074/jbc.271.31.18295.
214. Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science 298, 789-791. doi: 10.1126/science.1074069.
215. Shah, K., Desilva, S., and Abbruscato, T. (2012). The role of glucose transporters in brain disease: diabetes and Alzheimer's Disease. Int. J. Mol. Sci. 13, 12629-12655. doi: 10.3390/ijms131012629.
216. Shulman, G. I., Rothman, D. L., Jue, T., Stein, P., DeFronzo, R. A., and Shulman, R. G. (1990). Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322, 223-228. doi: 10.1056/nejm199001253220403.
217. Sims, N. R., Finegan, J. M., Blass, J. P., Bowen, D. M., and Neary, D. (1987). Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res. 436, 30-38. doi: 10.1016/0006-8993(87)91553-8.
218. Singh, R., Barden, A., Mori, T., and Beilin, L. (2001). Advanced glycation end-products: a review. Diabetologia 44, 129-146. doi: 10.1007/s001250051591.
219. Skeberdis, V. A., Lan, J., Zheng, X., Zukin, R. S., and Bennett, M. V. (2001). Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc. Natl. Acad. Sci. U S A 98, 3561-3566. doi: 10.1073/pnas.051634698.
220. Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., Bookheimer, S. Y., et al. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U S A 97, 6037-6042. doi: 10.1073/pnas.090106797.
221. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292. doi: 10.1016/j.jalz.2011.03.003.
222. Sridhar, G. R., Lakshmi, G., and Nagamani, G. (2015). Emerging links between type 2 diabetes and Alzheimer's disease. World J. Diabetes 6, 744-751. doi: 10.4239/wjd.v6.i5.744.
223. Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., et al. (2011). Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 32, 763-777. doi: 10.1016/j.neurobiolaging.2009.04.016.
224. Srodulski, S., Sharma, S., Bachstetter, A. B., Brelsfoard, J. M., Pascual, C., Xie, X. S., et al. (2014). Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol. Neurodegener. 9:30. doi: 10.1186/1750-1326-9-30.
225. Starkov, A. A., Fiskum, G., Chinopoulos, C., Lorenzo, B. J., Browne, S. E., Patel, M. S., et al. (2004). Mitochondrial a-ketoglutarate dehydrogenase complex generates reactive oxygen species. J. Neurosci. 24, 7779-7788. doi: 10.1523/JNEUROSCI.1899-04.2004.
226. Stockhorst, U., De Fries, D., Steingrueber, H.-J., and Scherbaum, W. A. (2004). Insulin and the CNS: effects on food intake, memory and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 83, 47-54. doi: 10.1016/j.physbeh.2004.07.022.
227. Strachan, M. W. (2011). R D Lawrence Lecture 2010. The brain as a target organ in Type 2 diabetes: exploring the links with cognitive impairment and dementia. Diabet. Med. 28, 141-147. doi: 10.1111/j.1464-5491.2010.03199.x.
228. Stranahan, A. M., Norman, E. D., Lee, K., Cutler, R. G., Telljohann, R. S., Egan, J. M., et al. (2008). Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18, 1085-1088. doi: 10.1002/hipo.20470.
229. Sudoh, S., Frosch, M. P., and Wolf, B. A. (2002). Differential effects of proteases involved in intracellular degradation of amyloid b-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 41, 1091-1099. doi: 10.1021/bi011193l.
230. Sun, G. Y., Shelat, P. B., Jensen, M. B., He, Y., Sun, A. Y., and Simonyi, A. (2010). Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Med. 12, 133-148. doi: 10.1007/s12017-009-8092-z.
231. Sun, G. Y., Xu, J., Jensen, M. D., and Simonyi, A. (2004). Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 45, 205-213. doi: 10.1194/jlr.r300016-jlr200.
232. Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., and Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68, 930-941. doi: 10.1016/j.biopsych.2010.06.012.
233. Swerdlow, R. H., Burns, J. M., and Khan, S. M. (2010). The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 20, S265-S279. doi: 10.3233/JAD-2010-100339.
234. Swerdlow, R. H., and Khan, S. M. (2004). A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypotheses 63, 8-20. doi: 10.1016/j.mehy.2003.12.045.
235. Szendroedi, J., Phielix, E., and Roden, M. (2011). The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 92-103. doi: 10.1038/nrendo.2011.138.
236. Takeda, S., Sato, N., Ikimura, K., Nishino, H., Rakugi, H., and Morishita, R. (2013). Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol. Aging 34, 2064-2070. doi: 10.1016/j.neurobiolaging.2013.02.010.
237. Tamaki, C., Ohtsuki, S., and Terasaki, T. (2007). Insulin facilitates the hepatic clearance of plasma amyloid ß-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol. Pharmacol. 72, 850-855. doi: 10.1124/mol.107.036913.
238. Taylor, R. W., and Turnbull, D. M. (2005). Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 6, 389-402. doi: 10.1038/nrg1606.
239. Tilvis, R. S., Kähönen-Väre, M. H., Jolkkonen, J., Valvanne, J., Pitkala, K. H., and Strandberg, T. E. (2004). Predictors of cognitive decline and mortality of aged people over a 10-year period. J. Gerontol. A Biol. Sci. Med. Sci. 59, 268-274. doi: 10.1093/gerona/59.3.m268.
240. Townsend, M., Mehta, T., and Selkoe, D. J. (2007). Soluble Aß inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282, 33305-33312. doi: 10.1074/jbc.M610390200.
241. Tremblay, S., Ouellet, R., Bénard, F., and Cunnane, S. C. (2008). Automated synthesis of 11C-ß-hydroxybutyrate by enzymatic conversion of 11C-acetoacetate using ß-hydroxybutyrate dehydrogenase. J. Labelled Comp. Radiopharm. 51, 242-245. doi: 10.1002/jlcr.1504.
242. Tremblay, S., Ouellet, R., Rodrigue, S., Langlois, R., Bénard, F., and Cunnane, S. C. (2007). Automated synthesis of 11C-acetoacetic acid, a key alternate brain fuel to glucose. Appl. Radiat. Isot. 65, 934-940. doi: 10.1016/j.apradiso.2007.03.015.
243. Unger, J. W., Livingston, J. N., and Moss, A. M. (1991). Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog. Neurobiol. 36, 343-362. doi: 10.1016/0301-0082(91)90015-s.
244. Unoki, H., Bujo, H., Yamagishi, S., Takeuchi, M., Imaizumi, T., and Saito, Y. (2007). Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res. Clin. Pract. 76, 236-244. doi: 10.1016/j.diabres.2006.09.016.
245. Unoki, H., and Yamagishi, S. (2008). Advanced glycation end products and insulin resistance. Curr. Pharm. Des. 14, 987-989. doi: 10.2174/138161208784139747.
246. Vaishnavi, S. N., Vlassenko, A. G., Rundle, M. M., Snyder, A. Z., Mintun, M. A., and Raichle, M. E. (2010). Regional aerobic glycolysis in the human brain. Proc. Natl. Acad. Sci. U S A 107, 17757-17762. doi: 10.1073/pnas.1010459107.
247. Vanhanen, M., Koivisto, K., Kuusisto, J., Mykkänen, L., Helkala, E. L., Hänninen, T., et al. (1998). Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 21, 398-402. doi: 10.2337/diacare.21.3.398.
248. Vlassenko, A. G., Vaishnavi, S. N., Couture, L., Sacco, D., Shannon, B. J., Mach, R. H., et al. (2010). Spatial correlation between brain aerobic glycolysis and amyloid-ß (Aß) deposition. Proc. Natl. Acad. Sci. U S A 107, 17763-17767. doi: 10.1073/pnas.1010461107.
249. Wallace, D. C., Fan, W., and Procaccio, V. (2010). Mitochondrial energetics and therapeutics. Annu. Rev. Pathol. 5, 297-348. doi: 10.1146/annurev.pathol.4.110807.092314.
250. Wallum, B. J., Taborsky, G. J. Jr., Porte, D. Jr., Figlewicz, D. P., Jacobson, L., Beard, J. C., et al. (1987). Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J. Clin. Endocrinol. Metab. 64, 190-194. doi: 10.1210/jcem-64-1-190.
251. Wang, X., Su, B., Lee, H. G., Li, X., Perry, G., Smith, M. A., et al. (2009). Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 29, 9090-9103. doi: 10.1523/JNEUROSCI.1357-09.2009.
252. Wang, X., Su, B., Siedlak, S. L., Moreira, P. I., Fujioka, H., Wang, Y., et al. (2008). Amyloid-ß overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U S A 105, 19318-19323. doi: 10.1073/pnas.0804871105.
253. Watson, G. S., and Craft, S. (2006). Insulin resistance, inflammation, and cognition in Alzheimer's disease: lessons for multiple sclerosis. J. Neurol. Sci. 245, 21-33. doi: 10.1016/j.jns.2005.08.017.
254. Wautier, J. L., Zoukourian, C., Chappey, O., Wautier, M. P., Guillausseau, P. J., Cao, R., et al. (1996). Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97, 238-243. doi: 10.1172/jci118397.
255. Wei, Y. H., and Lee, H. C. (2002). Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp. Biol. Med. (Maywood) 227, 671-682. doi: 10.1177/153537020222700901.
256. Werther, G. A., Hogg, A., Oldfield, B. J., Mckinley, M. J., Figdor, R., Allen, A. M., et al. (1987). Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 121, 1562-1570. doi: 10.1210/endo-121-4-1562.
257. White, H., Pieper, C., and Schmader, K. (1998). The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J. Am. Geriatr. Soc. 46, 1223-1227. doi: 10.1111/j.1532-5415.1998.tb04537.x.
258. Whitmer, R. A., Gustafson, D. R., Barrett-Connor, E., Haan, M. N., Gunderson, E. P., and Yaffe, K. (2008). Central obesity and increased risk of dementia more than three decades later. Neurology 71, 1057-1064. doi: 10.1212/01.wnl.0000306313.89165.ef.
259. Willette, A. A., Bendlin, B. B., Starks, E. J., Birdsill, A. C., Johnson, S. C., Christian, B. T., et al. (2015a). Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol. 72, 1013-1020. doi: 10.1001/jamaneurol.2015.0613.
260. Willette, A. A., Modanlo, N., and Kapogiannis, D. (2015b). Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. Diabetes 64, 1933-1940. doi: 10.2337/db14-1507.
261. Woods, S. C., Seeley, R. J., Baskin, D. G., and Schwartz, M. W. (2003). Insulin and the blood-brain barrier. Curr. Pharm. Des. 9, 795-800. doi: 10.2174/1381612033455323.
262. Wyss-Coray, T., and Rogers, J. (2012). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2:a006346. doi: 10.1101/cshperspect.a006346.
263. Yaffe, K., Blackwell, T., Kanaya, A. M., Davidowitz, N., Barrett-Connor, E., and Krueger, K. (2004). Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63, 658-663. doi: 10.1212/01.WNL.0000134666.64593.ba.
264. Yaffe, K., Blackwell, T., Whitmer, R. A., Krueger, K., and Barrett Connor, E. (2006). Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J. Nutr. Health Aging 10, 293-295.
265. Yamagishi, S., Maeda, S., Matsui, T., Ueda, S., Fukami, K., and Okuda, S. (2012). Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim. Biophys. Acta 1820, 663-671. doi: 10.1016/j.bbagen.2011.03.014.
266. Yao, J., and Brinton, R. D. (2011). Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Curr. Pharm. Des. 17, 3474-3479. doi: 10.2174/138161211798072517.
267. Yao, J., and Brinton, R. D. (2012). Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv. Pharmacol. 64, 327-371. doi: 10.1016/b978-0-12-394816-8.00010-6.
268. Yao, J., Hamilton, R. T., Cadenas, E., and Brinton, R. D. (2010). Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim. Biophys. Acta 1800, 1121-1126. doi: 10.1016/j.bbagen.2010.06.002.
269. Yao, J., Irwin, R., Chen, S., Hamilton, R., Cadenas, E., and Brinton, R. D. (2012). Ovarian hormone loss induces bioenergetic deficits and mitochondrial ß-amyloid. Neurobiol. Aging 33, 1507-1521. doi: 10.1016/j.neurobiolaging.2011.03.001.
270. Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., and Brinton, R. D. (2009). Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U S A 106, 14670-14675. doi: 10.1073/pnas.0903563106.
271. Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., and Brinton, R. D. (2011). Shift in brain metabolism in late onset alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol. Aspects Med. 32, 247-257. doi: 10.1016/j.mam.2011.10.005.
272. Yan, L. M., Velkova, A., and Kapurniotu, A. (2014). Molecular characterization of the hetero-assembly of ß-amyloid peptide with islet amyloid polypeptide. Curr. Pharm. Des. 20, 1182-1191. doi: 10.2174/13816128113199990064.
273. Zhang, Y., Zhou, B., Deng, B., Zhang, F., Wu, J., Wang, Y., et al. (2013). Amyloid-ß induces hepatic insulin resistance in vivo via JAK2. Diabetes 62, 1159-1166. doi: 10.2337/db12-0670.
274. Zhao, W. Q., and Alkon, D. L. (2001). Role of insulin and insulin receptor in learning and memory. Mol. Cell. Endocrinol. 177, 125-134. doi: 10.1016/s0303-7207(01)00455-5.
275. Zhao, W.-Q., Chen, H., Quon, M. J., and Alkon, D. L. (2004). Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490, 71-81. doi: 10.1016/j.ejphar.2004.02.045.
276. Zhao, W., Chen, H., Xu, H., Moore, E., Meiri, N., Quon, M. J., et al. (1999). Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 274, 34893-34902. doi: 10.1074/jbc.274.49.34893.
277. Zhu, D., Lai, Y., Shelat, P. B., Hu, C., Sun, G. Y., and Lee, J. C. (2006). Phospholipases A2 mediate amyloid-ß peptide-induced mitochondrial dysfunction. J. Neurosci. 26, 11111-11119. doi: 10.1523/jneurosci.3505-06.2006.
278. Zhao, N., Liu, C. C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., et al. (2017). Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 96, 115.e5-129.e5. doi: 10.1016/j.neuron.2017.09.003.
279. Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., et al. (2004). Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J. Neurosci. 24, 11120-11126. doi: 10.1523/JNEUROSCI.2860-04.2004.